BioCentury | Jun 28, 2018
Distillery Therapeutics

Infectious disease

...steps could include testing the SCCs in models of MRSA infection. Eli Lilly and Co., Kuhnil Pharmaceutical Co. Ltd....
BioCentury | Mar 17, 2017
Company News

Kitov, Kuhnil deal

...Kitov granted Kuhnil exclusive South Korean rights to develop and commercialize KIT-302 . Kitov is eligible...
...develop and commercialize KIT-302 . Kitov is eligible for undisclosed regulatory milestones and double-digit royalties. Kuhnil...
...NASDAQ:KTOV), Tel Aviv, Israel Kuhnil Pharmaceutical Co. Ltd. , Seoul, South Korea Business: Cardiovascular, Neurology Chris Lieu Kitov Pharmaceuticals Holdings Ltd. Kuhnil Pharmaceutical Co. Ltd. Calcium...
BioCentury | Feb 22, 2017
Distillery Techniques

Chemistry

...steps include expanding the biocalatytic method to additional drug-like scaffolds. Eli Lilly and Co. , Kuhnil Pharmaceutical Co. Ltd....
BioCentury | May 12, 2014
Clinical News

Nimotuzumab: Phase III discontinued

...Feb. 18, 2013). Oncoscience licensed European rights to nimotuzumab; Daiichi Sankyo licensed rights in Japan; Kuhnil...
...Bukit Batok, Singapore Oncoscience AG , Wedel, Germany Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Kuhnil Pharmaceutical Co. Ltd....
BioCentury | Dec 10, 2012
Company News

InnoKeys, YM BioSciences deal

...from YM, while Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568, Tokyo, Japan) licensed rights in Japan, Kuhnil Pharmaceutical Co. Ltd....
BioCentury | Nov 7, 2011
Clinical News

Nimotuzumab: Preliminary Phase II data

...Cuba). Oncoscience has European rights to nimotuzumab from YM, while Daiichi licensed rights in Japan, Kuhnil...
...YM BioSciences Inc. (TSX:YM; NYSE-A:YMI), Mississauga, Ontario Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568), Tokyo, Japan Kuhnil Pharmaceutical Co. Ltd....
BioCentury | Oct 10, 2011
Clinical News

Nimotuzumab: Phase II data

...Cuba). Oncoscience has European rights to nimotuzumab from YM, while Daiichi licensed rights in Japan, Kuhnil...
...YM BioSciences Inc. (TSX:YM; NYSE-A:YMI), Mississauga, Ontario Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568), Tokyo, Japan Kuhnil Pharmaceutical Co. Ltd....
BioCentury | Jun 27, 2011
Clinical News

Nimotuzumab cancer data

...Cuba). Oncoscience has European rights to nimotuzumab from YM, while Daiichi licensed rights in Japan, Kuhnil...
...YM BioSciences Inc. (TSX:YM; NYSE-A:YMI), Mississauga, Ontario Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568), Tokyo, Japan Kuhnil Pharmaceutical Co. Ltd....
BioCentury | Jun 13, 2011
Clinical News

Nimotuzumab: Phase II discontinued

...Cuba). Oncoscience has European rights to nimotuzumab from YM, while Daiichi licensed rights in Japan, Kuhnil...
...YM BioSciences Inc. (TSX:YM; NYSE-A:YMI), Mississauga, Ontario Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568), Tokyo, Japan Kuhnil Pharmaceutical Co. Ltd....
BioCentury | Jun 13, 2011
Clinical News

Nimotuzumab: Phase II discontinued

...Cuba). Oncoscience has European rights to nimotuzumab from YM, while Daiichi licensed rights in Japan, Kuhnil...
...YM BioSciences Inc. (TSX:YM; NYSE-A:YMI), Mississauga, Ontario Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568), Tokyo, Japan Kuhnil Pharmaceutical Co. Ltd....
Items per page:
1 - 10 of 31
BioCentury | Jun 28, 2018
Distillery Therapeutics

Infectious disease

...steps could include testing the SCCs in models of MRSA infection. Eli Lilly and Co., Kuhnil Pharmaceutical Co. Ltd....
BioCentury | Mar 17, 2017
Company News

Kitov, Kuhnil deal

...Kitov granted Kuhnil exclusive South Korean rights to develop and commercialize KIT-302 . Kitov is eligible...
...develop and commercialize KIT-302 . Kitov is eligible for undisclosed regulatory milestones and double-digit royalties. Kuhnil...
...NASDAQ:KTOV), Tel Aviv, Israel Kuhnil Pharmaceutical Co. Ltd. , Seoul, South Korea Business: Cardiovascular, Neurology Chris Lieu Kitov Pharmaceuticals Holdings Ltd. Kuhnil Pharmaceutical Co. Ltd. Calcium...
BioCentury | Feb 22, 2017
Distillery Techniques

Chemistry

...steps include expanding the biocalatytic method to additional drug-like scaffolds. Eli Lilly and Co. , Kuhnil Pharmaceutical Co. Ltd....
BioCentury | May 12, 2014
Clinical News

Nimotuzumab: Phase III discontinued

...Feb. 18, 2013). Oncoscience licensed European rights to nimotuzumab; Daiichi Sankyo licensed rights in Japan; Kuhnil...
...Bukit Batok, Singapore Oncoscience AG , Wedel, Germany Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Kuhnil Pharmaceutical Co. Ltd....
BioCentury | Dec 10, 2012
Company News

InnoKeys, YM BioSciences deal

...from YM, while Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568, Tokyo, Japan) licensed rights in Japan, Kuhnil Pharmaceutical Co. Ltd....
BioCentury | Nov 7, 2011
Clinical News

Nimotuzumab: Preliminary Phase II data

...Cuba). Oncoscience has European rights to nimotuzumab from YM, while Daiichi licensed rights in Japan, Kuhnil...
...YM BioSciences Inc. (TSX:YM; NYSE-A:YMI), Mississauga, Ontario Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568), Tokyo, Japan Kuhnil Pharmaceutical Co. Ltd....
BioCentury | Oct 10, 2011
Clinical News

Nimotuzumab: Phase II data

...Cuba). Oncoscience has European rights to nimotuzumab from YM, while Daiichi licensed rights in Japan, Kuhnil...
...YM BioSciences Inc. (TSX:YM; NYSE-A:YMI), Mississauga, Ontario Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568), Tokyo, Japan Kuhnil Pharmaceutical Co. Ltd....
BioCentury | Jun 27, 2011
Clinical News

Nimotuzumab cancer data

...Cuba). Oncoscience has European rights to nimotuzumab from YM, while Daiichi licensed rights in Japan, Kuhnil...
...YM BioSciences Inc. (TSX:YM; NYSE-A:YMI), Mississauga, Ontario Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568), Tokyo, Japan Kuhnil Pharmaceutical Co. Ltd....
BioCentury | Jun 13, 2011
Clinical News

Nimotuzumab: Phase II discontinued

...Cuba). Oncoscience has European rights to nimotuzumab from YM, while Daiichi licensed rights in Japan, Kuhnil...
...YM BioSciences Inc. (TSX:YM; NYSE-A:YMI), Mississauga, Ontario Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568), Tokyo, Japan Kuhnil Pharmaceutical Co. Ltd....
BioCentury | Jun 13, 2011
Clinical News

Nimotuzumab: Phase II discontinued

...Cuba). Oncoscience has European rights to nimotuzumab from YM, while Daiichi licensed rights in Japan, Kuhnil...
...YM BioSciences Inc. (TSX:YM; NYSE-A:YMI), Mississauga, Ontario Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568), Tokyo, Japan Kuhnil Pharmaceutical Co. Ltd....
Items per page:
1 - 10 of 31